Ascendant Solutions, Inc. (OTC:ASDS) has announced the third quarter earnings for 2009. It’s consolidated net income for the quarter is $75,000. The company experienced a net loss of $85,000 the year before during the same period. The consolidated net income for the nine months ending September 30, 2009 was $223,000 in comparison to $1,326,000 for the nine months ended in 2008. The full report of financial results may be found online at http://www.ascendantsolutions.com/.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
Ascendant Solutions, Inc. is a financial services company, which through its subsidiaries, is seeking to, or has invested in, or acquired healthcare, manufacturing, distribution or service companies. It conducts various real estate activities, performing real estate advisory services for corporate clients, and through an affiliate, purchase real estate assets, as a principal investor. It has three segments: healthcare, real estate advisory services, and corporate and other business. The healthcare segment provides products and services through retail pharmacies, including specialty compounding pharmacy services; the real estate advisory services segment provides tenant representation, lease management services, capital markets advisory services and strategic real estate advisory services, and corporate and other segment provides corporate administration and investments. In November 2007, it sold its ownership interests in Park InfusionCare, L.P. to Maverick Healthcare Group, LLC.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
